Furthermore, the treatment of chronic cholestatic pruritus represents a clinical challenge: Rifampicin is a PXR-agonist, which increases the metabolism and secretion of pruritogenic substances and is often used as first-line therapy in children but not consistently effective (32, 33). This evidence concerns the gene NR1I2 and Pruritus.